BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 22695330)

  • 21. APOL1 Genotype and Race Differences in Incident Albuminuria and Renal Function Decline.
    Peralta CA; Bibbins-Domingo K; Vittinghoff E; Lin F; Fornage M; Kopp JB; Winkler CA
    J Am Soc Nephrol; 2016 Mar; 27(3):887-93. PubMed ID: 26180129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study.
    Tin A; Grams ME; Maruthur NM; Astor BC; Couper D; Mosley TH; Fornage M; Parekh RS; Coresh J; Kao WH
    Clin J Am Soc Nephrol; 2015 May; 10(5):784-90. PubMed ID: 25887069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APOL1 variants associate with increased risk of CKD among African Americans.
    Foster MC; Coresh J; Fornage M; Astor BC; Grams M; Franceschini N; Boerwinkle E; Parekh RS; Kao WH
    J Am Soc Nephrol; 2013 Sep; 24(9):1484-91. PubMed ID: 23766536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target.
    Kormann R; Jannot AS; Narjoz C; Ribeil JA; Manceau S; Delville M; Joste V; Prié D; Pouchot J; Thervet E; Courbebaisse M; Arlet JB
    Br J Haematol; 2017 Oct; 179(2):323-335. PubMed ID: 28699644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generalization of associations of kidney-related genetic loci to American Indians.
    Franceschini N; Haack K; Almasy L; Laston S; Lee ET; Best LG; Fabsitz RR; MacCluer JW; Howard BV; Umans JG; Cole SA
    Clin J Am Soc Nephrol; 2014 Jan; 9(1):150-8. PubMed ID: 24311711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes.
    Freedman BI; Langefeld CD; Lu L; Palmer ND; Smith SC; Bagwell BM; Hicks PJ; Xu J; Wagenknecht LE; Raffield LM; Register TC; Carr JJ; Bowden DW; Divers J
    Kidney Int; 2015 Jan; 87(1):176-81. PubMed ID: 25054777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.
    Gutiérrez OM; Judd SE; Irvin MR; Zhi D; Limdi N; Palmer ND; Rich SS; Sale MM; Freedman BI
    Nephrol Dial Transplant; 2016 Apr; 31(4):602-8. PubMed ID: 26152403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Race, APOL1 Risk Variants, and Clinical Outcomes among Older Adults: The ARIC Study.
    Chen TK; Coresh J; Daya N; Ballew SH; Tin A; Crews DC; Grams ME
    J Am Geriatr Soc; 2021 Jan; 69(1):155-163. PubMed ID: 32894582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.
    Hawkins GA; Friedman DJ; Lu L; McWilliams DR; Chou JW; Sajuthi S; Divers J; Parekh RS; Li M; Genovese G; Pollack MR; Hicks PJ; Bowden DW; Ma L; Freedman BI; Langefeld CD
    Am J Nephrol; 2015; 42(2):99-106. PubMed ID: 26343748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma biomarkers are associated with renal outcomes in individuals with APOL1 risk variants.
    Nadkarni GN; Chauhan K; Verghese DA; Parikh CR; Do R; Horowitz CR; Bottinger EP; Coca SG
    Kidney Int; 2018 Jun; 93(6):1409-1416. PubMed ID: 29685497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of Association of the APOL1 G3 Haplotype in African Americans with ESRD.
    Palmer ND; Ng MC; Langefeld CD; Divers J; Lea JP; Okusa MD; Kimberly RP; Bowden DW; Freedman BI
    J Am Soc Nephrol; 2015 May; 26(5):1021-5. PubMed ID: 25249559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans.
    Freedman BI; Langefeld CD; Lu L; Divers J; Comeau ME; Kopp JB; Winkler CA; Nelson GW; Johnson RC; Palmer ND; Hicks PJ; Bostrom MA; Cooke JN; McDonough CW; Bowden DW
    PLoS Genet; 2011 Jun; 7(6):e1002150. PubMed ID: 21698141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population genetics of chronic kidney disease: the evolving story of APOL1.
    Wasser WG; Tzur S; Wolday D; Adu D; Baumstein D; Rosset S; Skorecki K
    J Nephrol; 2012; 25(5):603-18. PubMed ID: 22878977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low prevalence of apolipoprotein L1 gene variants in Black South Africans with hypertension-attributed chronic kidney disease
.
    Nqebelele NU; Dickens C; Dix-Peek T; Duarte R; Naicker S
    Clin Nephrol; 2019 Jan; 91(1):40-47. PubMed ID: 30369398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testing for High-Risk APOL1 Alleles in Potential Living Kidney Donors.
    Riella LV; Sheridan AM
    Am J Kidney Dis; 2015 Sep; 66(3):396-401. PubMed ID: 26049628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of coding variants identified from exome sequencing resources for association with diabetic and non-diabetic nephropathy in African Americans.
    Bailey JNC; Palmer ND; Ng MCY; Bonomo JA; Hicks PJ; Hester JM; Langefeld CD; Freedman BI; Bowden DW
    Hum Genet; 2014 Jun; 133(6):769-779. PubMed ID: 24385048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Copy Number Variation at the APOL1 Locus.
    Ruchi R; Genovese G; Lee J; Charoonratana VT; Bernhardy AJ; Alper SL; Kopp JB; Thadhani R; Friedman DJ; Pollak MR
    PLoS One; 2015; 10(5):e0125410. PubMed ID: 25933006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. APOL1 variants and kidney disease in people of recent African ancestry.
    Genovese G; Friedman DJ; Pollak MR
    Nat Rev Nephrol; 2013 Apr; 9(4):240-4. PubMed ID: 23438974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma apolipoprotein L1 levels do not correlate with CKD.
    Bruggeman LA; O'Toole JF; Ross MD; Madhavan SM; Smurzynski M; Wu K; Bosch RJ; Gupta S; Pollak MR; Sedor JR; Kalayjian RC
    J Am Soc Nephrol; 2014 Mar; 25(3):634-44. PubMed ID: 24231663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume.
    Freedman BI; Gadegbeku CA; Bryan RN; Palmer ND; Hicks PJ; Ma L; Rocco MV; Smith SC; Xu J; Whitlow CT; Wagner BC; Langefeld CD; Hawfield AT; Bates JT; Lerner AJ; Raj DS; Sadaghiani MS; Toto RD; Wright JT; Bowden DW; Williamson JD; Sink KM; Maldjian JA; Pajewski NM; Divers J
    Kidney Int; 2016 Aug; 90(2):440-449. PubMed ID: 27342958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.